Solid-phase syntheses of two deacetyl-thymosin alpha 1 analogues with substitution at position 21 and their effects on low E-rosette-forming lymphocytes of uremic patients.
Abiko. T T; Sekino. H H
Key Findings
- Two deacetyl‑thymosin‑alpha‑1 analogues were created: one with a normal phenylalanine (Phe) at position 21 and one with a fluorinated phenylalanine (Phe(4F)).
- The fluorinated analogue showed a markedly stronger restorative effect on low E‑rosette‑forming lymphocytes in uremic (kidney‑failure) patients.
- The non‑fluorinated analogue had similar potency to the standard deacetyl‑thymosin‑alpha‑1 in the same patient group.
Practical Outcomes
- For most biohackers, this study doesn’t provide a new protocol or dosage for healthy people. It does suggest that small chemical tweaks (like adding fluorine) can boost the immune‑modulating activity of thymosin‑alpha‑1, which may be relevant for future supplement designs, but more research in healthy populations is needed before any actionable use.
Summary
Scientists made two slightly altered versions of the immune‑boosting peptide thymosin‑alpha‑1 and tested them on kidney‑failure patients with weak immune cells. The version that had a fluorine atom added (a fluorinated phenylalanine at position 21) helped the patients' immune cells recover better than the non‑fluorinated version, which performed about the same as the original peptide.
Abstract
Two deacetyl-thymosin alpha 1 analogues containing Phe or Phe(4F) at position 21 were synthesized by the manual solid-phase method and their immunological effects on the low E-rosette-forming lymphocytes of uremic patients were studied. Fluorination of the p-position of Phe21 resulted in a marked restorative effect on the low E-rosette-forming lymphocytes of uremic patients compared with that of [Phe21]deacetyl-thymosin alpha 1. The synthetic [Phe21]deacetyl-thymosin alpha 1 was approximately equal in potency to our synthetic deacetyl-thymosin alpha 1 in uremic patients.
Study Information
pubmed
1992